Clinical Trial Update: Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on TroVax vaccine with IL-2 in renal cell carcinoma assessing safety and biological activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• IL-2 (Interleukin-2)
• TroVax

Snippet

Sponsor: Oxford BioMedica | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED